Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IDEC-152 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| IDEC-152 | DRUG | 6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4 |
Inclusion Criteria: * Signed IRB-approved informed consent. * Greater than 18 years of age * Proof of CD23+ CLL or small lymphocytic lymphoma (SLL) * Progressive disease after at least 1 course of chemotherapy * Acceptable hematologic status, liver function, renal function, and pulmonary function *...
IDEC-152 is an investigational small molecule being studied for the treatment of Chronic Lymphocytic Leukemia (CLL). It was evaluated in a Phase 1 clinical trial to assess its safety and efficacy in patients with this condition. The drug is not approved and remains in clinical development.
IDEC-152 is being developed by Biogen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BIIB. The company sponsored the clinical trial of this investigational drug for Chronic Lymphocytic Leukemia.
IDEC-152 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was an uncontrolled, non-randomized study. The drug is investigational and has not been approved by regulatory authorities for any use.
IDEC-152 has been studied in one completed clinical trial, identified as NCT00046488. This Phase 1 study, titled 'Safety and Efficacy of IDEC-152 in the Treatment of Chronic Lymphocytic Leukemia (CLL),' enrolled 70 participants in the United States and was open to adults aged 18 years and older.
IDEC-152 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial for Chronic Lymphocytic Leukemia. The drug remains in clinical development and has not received marketing approval from the FDA or any other regulatory agency.